Inotiv, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Inotiv, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | $547.66M | Jan 13, 2023 |
| FY2022 | Sep 30, 2021 | $89.61M | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | $60.47M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $43.62M | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | $26.35M | Dec 26, 2019 |
| FY2019 | Jul 2, 2018 | $2.85M | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $24.24M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $20.44M | Dec 22, 2017 |
| FY2016 | Sep 30, 2015 | $22.70M | Dec 28, 2016 |
| FY2015 | Sep 30, 2014 | $24.58M | Dec 24, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $513.02M | Dec 5, 2025 |
| FY2025 | Sep 30, 2024 | $490.74M | Dec 5, 2025 |
| FY2025 | Sep 30, 2023 | $572.43M | Dec 5, 2025 |
| FY2023 | Sep 30, 2022 | $547.66M | Dec 12, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $24.24M | Dec 22, 2017 |
| FY2017 | Sep 30, 2016 | $20.44M | Dec 22, 2017 |
| FY2016 | Sep 30, 2015 | $22.70M | Dec 28, 2016 |
| FY2015 | Sep 30, 2014 | $24.58M | Dec 24, 2015 |
| FY2014 | Sep 30, 2013 | $22.07M | Dec 29, 2014 |
| FY2013 | Sep 30, 2012 | $28.21M | Dec 30, 2013 |
| FY2012 | Sep 30, 2011 | $33.14M | Oct 11, 2013 |
| FY2011 | Sep 30, 2010 | $28.78M | Dec 29, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $30.16M | Dec 21, 2021 |
| FY2021 | Sep 30, 2020 | $18.24M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $14.04M | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | $8.12M | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $7.70M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $4.43M | Dec 22, 2017 |
| FY2016 | Sep 30, 2015 | $7.49M | Dec 28, 2016 |
| FY2015 | Sep 30, 2014 | $7.96M | Dec 24, 2015 |
| FY2014 | Sep 30, 2013 | $7.06M | Dec 29, 2014 |
| FY2013 | Sep 30, 2012 | $6.84M | Dec 30, 2013 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($68.63M) | Dec 5, 2025 |
| FY2025 | Sep 30, 2024 | ($108.45M) | Dec 5, 2025 |
| FY2025 | Sep 30, 2023 | ($105.14M) | Dec 5, 2025 |
| FY2023 | Sep 30, 2022 | ($337.02M) | Dec 12, 2023 |
| FY2022 | Sep 30, 2021 | $10.90M | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | ($4.69M) | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | ($790.0K) | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | ($194.0K) | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $884.0K | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | ($3.23M) | Dec 22, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($30.90M) | Dec 5, 2025 |
| FY2025 | Sep 30, 2024 | ($86.41M) | Dec 5, 2025 |
| FY2025 | Sep 30, 2023 | ($81.46M) | Dec 5, 2025 |
| FY2023 | Sep 30, 2022 | ($263.45M) | Dec 12, 2023 |
| FY2022 | Sep 30, 2021 | ($5.62M) | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | ($3.06M) | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | ($153.0K) | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | $14.0K | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $1.28M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | ($3.04M) | Dec 22, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $405.0K | Dec 21, 2021 |
| FY2021 | Sep 30, 2020 | $617.0K | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $627.0K | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | $596.0K | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $465.0K | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $496.0K | Dec 22, 2017 |
| FY2016 | Sep 30, 2015 | $715.0K | Dec 28, 2016 |
| FY2015 | Sep 30, 2014 | $658.0K | Dec 24, 2015 |
| FY2014 | Sep 30, 2013 | $454.0K | Dec 29, 2014 |
| FY2013 | Sep 30, 2012 | $542.0K | Dec 30, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($10.46M) | Dec 5, 2025 |
| FY2025 | Sep 30, 2024 | ($6.81M) | Dec 5, 2025 |
| FY2025 | Sep 30, 2023 | $27.88M | Dec 5, 2025 |
| FY2023 | Sep 30, 2022 | ($5.22M) | Dec 12, 2023 |
| FY2022 | Sep 30, 2021 | $10.75M | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | $1.29M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $1.78M | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | $3.49M | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $1.24M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $1.06M | Dec 22, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $771.11M | Dec 5, 2025 |
| FY2025 | Sep 30, 2024 | $781.36M | Dec 5, 2025 |
| FY2024 | Sep 30, 2023 | $856.53M | Dec 4, 2024 |
| FY2023 | Sep 30, 2022 | $962.90M | Dec 12, 2023 |
| FY2022 | Sep 30, 2021 | $321.86M | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | $61.59M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $41.98M | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | $31.27M | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $20.42M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $21.13M | Dec 22, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $635.09M | Dec 5, 2025 |
| FY2025 | Sep 30, 2024 | $610.86M | Dec 5, 2025 |
| FY2024 | Sep 30, 2023 | $588.04M | Dec 4, 2024 |
| FY2023 | Sep 30, 2022 | $603.13M | Dec 12, 2023 |
| FY2022 | Sep 30, 2021 | $216.73M | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | $54.00M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $31.27M | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | $20.38M | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $11.95M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $13.67M | Dec 22, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $136.03M | Dec 5, 2025 |
| FY2025 | Sep 30, 2024 | $170.50M | Dec 5, 2025 |
| FY2024 | Sep 30, 2023 | $269.15M | Dec 4, 2024 |
| FY2023 | Sep 30, 2022 | $360.37M | Dec 12, 2023 |
| FY2022 | Sep 30, 2021 | $105.13M | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | $7.60M | Dec 21, 2021 |
| FY2021 | Sep 30, 2019 | $10.71M | Dec 21, 2021 |
| FY2020 | Sep 30, 2018 | $10.88M | Dec 22, 2020 |
| FY2019 | Sep 30, 2017 | $8.47M | Dec 26, 2019 |
| FY2018 | Sep 30, 2016 | $7.46M | Dec 21, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $94.29M | Dec 5, 2025 |
| FY2025 | Sep 30, 2024 | $94.29M | Dec 5, 2025 |
| FY2025 | Sep 30, 2023 | $94.29M | Dec 5, 2025 |
| FY2025 | Sep 30, 2022 | $157.83M | Dec 5, 2025 |
| FY2023 | Sep 30, 2021 | $51.93M | Dec 12, 2023 |
| FY2021 | Sep 30, 2020 | $4.37M | Dec 21, 2021 |
| FY2021 | Sep 30, 2019 | $3.62M | Dec 21, 2021 |
| FY2019 | Sep 30, 2018 | $3.07M | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | $38.0K | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | $38.0K | Dec 22, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($630.81M) | Dec 5, 2025 |
| FY2025 | Sep 30, 2024 | ($562.16M) | Dec 5, 2025 |
| FY2024 | Sep 30, 2023 | ($453.28M) | Dec 4, 2024 |
| FY2023 | Sep 30, 2022 | ($348.28M) | Dec 12, 2023 |
| FY2022 | Sep 30, 2021 | ($11.02M) | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | ($21.91M) | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | ($17.10M) | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | ($16.23M) | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | ($16.04M) | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | ($16.92M) | Dec 22, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $21.74M | Dec 5, 2025 |
| FY2025 | Sep 30, 2024 | $21.43M | Dec 5, 2025 |
| FY2024 | Sep 30, 2023 | $35.49M | Dec 4, 2024 |
| FY2023 | Sep 30, 2022 | $18.52M | Dec 12, 2023 |
| FY2022 | Sep 30, 2021 | $138.92M | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | $1.41M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $606.0K | Dec 22, 2020 |
| FY2020 | Sep 30, 2018 | $773.0K | Dec 22, 2020 |
| FY2019 | Sep 30, 2017 | $434.0K | Dec 26, 2019 |
| FY2018 | Sep 30, 2016 | $386.0K | Dec 21, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $402.12M | Dec 5, 2025 |
| FY2025 | Sep 30, 2024 | $393.34M | Dec 5, 2025 |
| FY2024 | Sep 30, 2023 | $377.75M | Dec 4, 2024 |
| FY2023 | Sep 30, 2022 | $350.66M | Dec 12, 2023 |
| FY2022 | Sep 30, 2021 | $170.32M | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | $25.05M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | $15.09M | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | $9.61M | Dec 26, 2019 |
| FY2017 | Sep 30, 2017 | $4.45M | Dec 22, 2017 |
| FY2016 | Sep 30, 2016 | $3.67M | Dec 28, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (2) | Dec 5, 2025 |
| FY2025 | Sep 30, 2024 | (4) | Dec 5, 2025 |
| FY2025 | Sep 30, 2023 | (4) | Dec 5, 2025 |
| FY2023 | Sep 30, 2022 | (13) | Dec 12, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | 0 | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | 0 | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | 0 | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Dec 22, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (2) | Dec 5, 2025 |
| FY2025 | Sep 30, 2024 | (4) | Dec 5, 2025 |
| FY2025 | Sep 30, 2023 | (4) | Dec 5, 2025 |
| FY2023 | Sep 30, 2022 | (13) | Dec 12, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | 0 | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | 0 | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | 0 | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Dec 22, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 34.36M | Dec 5, 2025 |
| FY2025 | Sep 30, 2024 | 26.02M | Dec 5, 2025 |
| FY2024 | Sep 30, 2023 | 25.78M | Dec 4, 2024 |
| FY2023 | Sep 30, 2022 | 25.60M | Dec 12, 2023 |
| FY2022 | Sep 30, 2021 | 15.93M | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | 10.98M | Dec 21, 2021 |
| FY2020 | Sep 30, 2019 | 10.51M | Dec 22, 2020 |
| FY2019 | Sep 30, 2018 | 10.25M | Dec 26, 2019 |
| FY2018 | Sep 30, 2017 | 8.24M | Dec 21, 2018 |
| FY2017 | Sep 30, 2016 | 8.11M | Dec 22, 2017 |